Details of the Drug

General Information of Drug (ID: DMB920Z)

Drug Name
Ceritinib
Synonyms
ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337; ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 558.1
Logarithm of the Partition Coefficient (xlogp) 6.4
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 41 hours [2]
Metabolism
The drug is metabolized via plasma []
Vd
The volume of distribution (Vd) of drug is 4230 L []
Chemical Identifiers
Formula
C28H36ClN5O3S
IUPAC Name
5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
Canonical SMILES
CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
InChI
InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
InChIKey
VERWOWGGCGHDQE-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
57379345
ChEBI ID
CHEBI:78432
CAS Number
1032900-25-6
DrugBank ID
DB09063
TTD ID
D04LVK
VARIDT ID
DR00228
ACDINA ID
D00115
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Modulator [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [4]
ALK tyrosine kinase receptor (ALK) OTV3P4V8 ALK_HUMAN Post-Translational Modifications [5]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [5]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [5]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Protein Interaction/Cellular Processes [5]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Protein Interaction/Cellular Processes [5]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Protein Interaction/Cellular Processes [5]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Gene/Protein Processing [5]
Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3) OTLUM9L7 PK3C3_HUMAN Gene/Protein Processing [5]
TNF receptor-associated factor 2 (TRAF2) OT1MEZZN TRAF2_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
ALK tyrosine kinase receptor (ALK) DTT ALK 7.19E-15 0.18 0.61
P-glycoprotein 1 (ABCB1) DTP P-GP 3.12E-33 -8.30E-01 -1.04E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ceritinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Brigatinib DM7W94S Major Decreased metabolism of Ceritinib caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [6]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Ceritinib caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [7]
PF-06463922 DMKM7EW Major Decreased metabolism of Ceritinib caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [8]
Osimertinib DMRJLAT Major Decreased metabolism of Ceritinib caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [9]
Pralsetinib DMWU0I2 Major Decreased metabolism of Ceritinib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [10]
Capmatinib DMYCXKL Major Decreased metabolism of Ceritinib caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [11]
Selpercatinib DMZR15V Major Decreased metabolism of Ceritinib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Ceritinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Ceritinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [13]
Arn-509 DMT81LZ Major Increased metabolism of Ceritinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Gilteritinib DMTI0ZO Major Decreased metabolism of Ceritinib caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Oliceridine DM6MDCF Major Decreased metabolism of Ceritinib caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [16]
Ivabradine DM0L594 Major Decreased metabolism of Ceritinib caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [13]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Ceritinib and Levalbuterol. Asthma [CA23] [17]
Troleandomycin DMUZNIG Major Decreased metabolism of Ceritinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [13]
Erdafitinib DMI782S Major Decreased metabolism of Ceritinib caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [18]
Pexidartinib DMS2J0Z Major Decreased metabolism of Ceritinib caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [19]
LY2835219 DM93VBZ Major Decreased metabolism of Ceritinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Tucatinib DMBESUA Major Decreased metabolism of Ceritinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [13]
Palbociclib DMD7L94 Major Decreased metabolism of Ceritinib caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [21]
PF-04449913 DMSB068 Major Decreased metabolism of Ceritinib caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [22]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Ceritinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [23]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Ceritinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [17]
Osilodrostat DMIJC9X Major Decreased metabolism of Ceritinib caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [12]
MK-8228 DMOB58Q Moderate Decreased metabolism of Ceritinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [14]
OPC-34712 DMHG57U Major Decreased metabolism of Ceritinib caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [24]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Ceritinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [25]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Ceritinib due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [14]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Ceritinib and Deutetrabenazine. Dystonic disorder [8A02] [26]
Ingrezza DMVPLNC Major Decreased metabolism of Ceritinib caused by Ingrezza mediated inhibition of CYP450 enzyme. Dystonic disorder [8A02] [27]
Stiripentol DMMSDOY Moderate Decreased metabolism of Ceritinib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Ceritinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Bay 80-6946 DMLOS5R Major Decreased clearance of Ceritinib due to the transporter inhibition by Bay 80-6946. Follicular lymphoma [2A80] [28]
Tazemetostat DMWP1BH Major Decreased metabolism of Ceritinib caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [29]
Ripretinib DM958QB Major Decreased metabolism of Ceritinib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [13]
Avapritinib DMK2GZX Major Decreased metabolism of Ceritinib caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [12]
Daclatasvir DMSFK9V Major Decreased metabolism of Ceritinib caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [12]
MK-1439 DM215WE Minor Decreased metabolism of Ceritinib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [30]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Ceritinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [26]
Cobicistat DM6L4H2 Major Decreased metabolism of Ceritinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [13]
Lesinurad DMUR64T Moderate Decreased metabolism of Ceritinib caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [31]
TP-434 DM5A31S Minor Decreased metabolism of Ceritinib caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [32]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Ceritinib caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [33]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Ceritinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [12]
Pemigatinib DM819JF Major Decreased metabolism of Ceritinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [12]
GDC-0199 DMH0QKA Major Decreased metabolism of Ceritinib caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [34]
IPI-145 DMWA24P Major Decreased metabolism of Ceritinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [35]
Acalabrutinib DM7GCVW Major Decreased metabolism of Ceritinib caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [36]
Selumetinib DMC7W6R Major Decreased metabolism of Ceritinib caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [37]
LGX818 DMNQXV8 Major Decreased metabolism of Ceritinib caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [38]
Ubrogepant DM749I3 Major Decreased metabolism of Ceritinib caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [39]
Rimegepant DMHOAUG Moderate Decreased metabolism of Ceritinib caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [40]
Lasmiditan DMXLVDT Moderate Decreased clearance of Ceritinib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [41]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Ceritinib and Siponimod. Multiple sclerosis [8A40] [13]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Ceritinib and Ozanimod. Multiple sclerosis [8A40] [26]
Deflazacort DMV0RNS Major Decreased metabolism of Ceritinib caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [12]
Fedratinib DM4ZBK6 Major Decreased metabolism of Ceritinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [12]
Rolapitant DM8XP26 Moderate Decreased clearance of Ceritinib due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [42]
Entrectinib DMMPTLH Major Decreased metabolism of Ceritinib caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [13]
S-297995 DM26IH8 Moderate Decreased metabolism of Ceritinib caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [12]
Olaparib DM8QB1D Major Decreased metabolism of Ceritinib caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [13]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Ceritinib and Rucaparib. Ovarian cancer [2C73] [26]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Ceritinib and Triclabendazole. Parasitic worm infestation [1F90] [26]
Istradefylline DM20VSK Major Decreased metabolism of Ceritinib caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [43]
Abametapir DM2RX0I Moderate Decreased metabolism of Ceritinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [44]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Ceritinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [45]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Ceritinib and Lefamulin. Pneumonia [CA40] [46]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Ceritinib and Relugolix. Prostate cancer [2C82] [26]
Darolutamide DMV7YFT Minor Decreased metabolism of Ceritinib caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [47]
Upadacitinib DM32B5U Major Decreased metabolism of Ceritinib caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [48]
Voxelotor DMCS6M5 Major Decreased metabolism of Ceritinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [49]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Ceritinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [12]
Larotrectinib DM26CQR Major Decreased metabolism of Ceritinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [13]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Ceritinib and LEE011. Solid tumour/cancer [2A00-2F9Z] [50]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Ceritinib and Pitolisant. Somnolence [MG42] [26]
Fostamatinib DM6AUHV Major Decreased metabolism of Ceritinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [51]
As-1670542 DMV05SW Moderate Decreased metabolism of Ceritinib caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [12]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Ceritinib and Lenvatinib. Thyroid cancer [2D10] [26]
Elagolix DMB2C0E Major Decreased metabolism of Ceritinib caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [52]
Fluticasone DMGCSVF Major Decreased metabolism of Ceritinib caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [53]
⏷ Show the Full List of 72 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ceritinib 150 mg capsule 150 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2015 Dec 12;3:54-66.
4 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
5 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells. Toxicol Appl Pharmacol. 2022 Sep 1;450:116156. doi: 10.1016/j.taap.2022.116156. Epub 2022 Jul 6.
6 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
7 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
8 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
9 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
10 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
11 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
12 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13 Cerner Multum, Inc. "Australian Product Information.".
14 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
15 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
16 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
17 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
18 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
19 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
20 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
21 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
22 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
23 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
24 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
25 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
26 Canadian Pharmacists Association.
27 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
28 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
29 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
30 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
31 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
32 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
33 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
34 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
35 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
36 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
37 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
38 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
39 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
40 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
41 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
42 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
43 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
44 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
45 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
46 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
47 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
48 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
49 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
50 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
51 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
52 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
53 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]